Company intelligence / Profile preview
Cessation Therapeutics
Chapel Hill, North Carolina, United Statescessationtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Preliminary data from Phase 1a first-in-human study showed CSX-1004 is safe and well-tolerated under the conditions tested. The exposure data were predictive of efficacy for blocking fentanyl-induced respiratory depression. In non-human primates, CSX-1004 provided robust and durable protection from life-threatening respiratory depression caused by high doses of fentanyl for at least 3 weeks after a single administration.[3][7]
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Monoclonal antibodies (mAbs)Immunobiologics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
McLean Hospital (a member of Mass General Brigham)National Institute on Drug Abuse (NIDA)
Beyond the preview
Go deeper on Cessation Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cessation Therapeutics.